ResMed is a proven dividend grower over 10 years while also having an attractive balance sheet risk profile with a low D/E ...

CVD™, including novel AI-CAC™ for earlier, more sensitive heart disease risk. HOUSTON, TX, UNITED STATES, August 27, 2025 /EINPresswire.com/ -- HeartLung Technologies is proud to announce that its ...

"I'm a nurse. No one knows just how short-staffed all positions in the hospital are. Short on doctors. Short on nurses. Short ...

Tyr Pharma's Phase 2 data for efzo in pulmonary sarcoidosis is difficult to interpret and not predictive for Phase 3. Read ...

Access to a webcast of the presentation will be available to investors and other interested parties by accessing Liquidia’s website at https://liquidia.com/investors/events-and-presentations. An ...

Savara’s Partner, TrilliumBiO, to Present Data on the Development of a Dried Blood Spot Test to Aid in the Diagnosis of aPAP ...

Michael W. Dryden, DVM, MS, PhD, DACVM (Parasitology), delivered a keynote address focused on canine heartworm disease on day ...

Live webcasts of the presentations may be accessed via the Investors section of the Connect website at investors.connectbiopharma.com . Archived replays of both events will be available on the website ...

Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and ...

Members of the Equillium management team will be available to participate in meetings with investors who are registered to attend the conference. Investors and the general public are invited to listen ...

Merck demonstrates ongoing commitment to advancing cardiovascular disease management and patient care with new data at the ESC Congress 2025: Rahway, New Jersey Tuesday, August 26 ...

Distinct profiles of underlying conditions may help predict the risk for severe RSV outcomes in hospitalized adults.